Tradestie Institutional Equity Comparison Engine
ORKA vs PVLA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ORKA Overall Edge
ORKA Captures Institutional Edge (3โ0 Pillars ยท 4โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Oruka Therapeutics, Inc. Common Stock (ORKA) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ORKA trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus PVLA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ORKA sits in BREAKOUT (19th %ile IV; Dealer Gamma Walls on Pro) against PVLA sits in CONSOLIDATION (2nd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
ORKA N/M vs PVLA N/M Fwd P/E
Growth & Margin Winner
ORKA
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner
ORKA
1Y +277.3% vs +80.2% ยท 52W Pos 82% vs 68%
Options & Structure Winner
ORKA
BREAKOUT (19th %ile IV) vs CONSOLIDATION (2nd %ile IV)
ORKA
NASDAQ
Oruka Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.53
-5.52% 1D
Market Cap
$7.1B
1M Return
+38.37%
1Y Return
+277.29%
Forward P/E
N/M
Unified AI Score
38.8 / 100
SELL
Tech 8.0
Fund 40.0
Flow 69.0
Mom 50.0
PVLA
NASDAQ
Palvella Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$145.03
-4.89% 1D
Market Cap
$2.2B
1M Return
+20.56%
1Y Return
+80.16%
Forward P/E
N/M
Unified AI Score
48.2 / 100
HOLD
Tech 35.0
Fund 53.0
Flow 67.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ORKA +277.29%
PVLA +80.16%
Spread: +197.13 pp (ORKA Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
ORKA TTM Op. Margin: 0.0%
PVLA TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ORKA vs PVLA. Trailing 12-month operating profitability (ORKA 0.0% vs PVLA 0.0%) and valuation multiples (ORKA N/M vs PVLA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ORKA | PVLA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $7.1B | $2.2B | Larger Scale | ORKA |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -18.1% | -63.4% | Higher ROE | ORKA |
| 52-Week Range Position Momentum | 82% ($25โ$116) | 68% ($72โ$180) | Stronger Trend | ORKA |
| Beta / 30D Volatility Risk Regime | 1.34ฮฒ ยท 66% Vol | 1.66ฮฒ ยท 75% Vol | Lower Realized Risk | ORKA |
| Unified Institutional Score Composite Signal | 38.8 / 100 (SELL) | 48.2 / 100 (HOLD) | Higher Composite | PVLA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ORKA vs PVLA Buy Guide
ORKA
BREAKOUT
141d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
19th %ile
IV Regime
Compressed (<25th %ile)
PVLA
CONSOLIDATION
70d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
2nd %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ORKA nor PVLA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.